Full text is available at the source.
Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus
Tirzepatide improves eating habits in Japanese type 2 diabetes patients, even without previous treatment with similar drugs
AI simplified
Abstract
Tirzepatide treatment resulted in a significant decrease in median hemoglobin A1c from 7.3% at baseline to 5.8% at 6 months.
- Mean body weight decreased from 87.7 kg at baseline to 79.6 kg at 6 months.
- The relative score of eating behaviors improved from 57.0 at baseline to 45.9 at 6 months.
- In the group naive to GLP-1 receptor agonists, HbA1c and body weight decreased steadily over 6 months.
- In the group previously treated with GLP-1 receptor agonists, reductions in HbA1c and body weight were most notable in the first 3 months.
- Changes in eating behavior scores did not significantly correlate with changes in glycemic control or body weight.
AI simplified